SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models
Clinical & Translational Immunology · 2022-01 · 11 (1)
DOI: 10.1002/cti2.1364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 29.12.2021. Verfasst von Chun-Bong Synn und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science College of Medicine Yonsei University Seoul Korea. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Objectives
AXL‐mediated activation of aberrant tyrosine kinase drives various oncogenic processes and facilitates an immunosuppressive microenvironment. We evaluated the anti‐tumor and anti‐metastatic activities of SKI‐G‐801, a small‐molecule inhibitor of AXL, alone and in combination with anti‐PD‐1 therapy.
Methods
In vitro pAXL inhibition by SKI‐G‐801 was performed in both human and mouse cancer cell lines. Immunocompetent mouse models of tumor were established to measure anti‐metastatic potential of SKI‐G‐801. Furthermore, SKI‐G‐801, anti‐PD‐1 or their combination was administered as an adjuvant or neoadjuvant in the 4T1 tumor model to assess their potential for clinical application.
Results
SKI‐G‐801 robustly inhibited pAXL expression in various cell lines. SKI‐G‐801 alone or in combination with anti‐PD‐1 potently inhibited metastasis in B16F10 melanoma, CT26 colon and 4T1 breast models. SKI‐G‐801 inhibited the growth of B16F10 and 4T1 tumor‐bearing mice but not immune‐deficient mice. An antibody depletion assay revealed that CD8 + T cells significantly contributed to SKI‐G‐801‐mediated survival. Anti‐PD‐1 and combination group were observed the increased CD8 + Ki67 + and effector T cells and M1 macrophage and decreased M2 macrophage, and granulocytic myeloid‐derived suppressor cell (G‐MDSC) compared to the control group. The neoadjuvant combination of SKI‐G‐801 and anti‐PD‐1 therapy achieved superior survival benefits by inducing more profound T‐cell responses in the 4T1 syngeneic mouse model.
Conclusion
SKI‐G‐801 significantly suppressed tumor metastasis and growth by enhancing anti‐tumor immune responses. Our results suggest that SKI‐G‐801 has the potential to overcome anti‐PD‐1 therapy resistance and allow more patients to benefit from anti‐PD‐1 therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Science College of Medicine Yonsei University Seoul Korea.
- Brain Korea 21 PLUS Project for Medical Science Yonsei University College of Medicine Seoul Korea.
- Oscotec Inc. Seongnam Korea.
- Yonsei Cancer Center Yonsei University College of Medicine Seoul Korea.
- JEUK Institute for Cancer Research Gumi Korea.
- Department of Hematology-Oncology Inje University Haeundae Paik Hospital Busan Korea.
ORCID-Profile: Chun-Bong Synn, Dong Kwon Kim, Eun Ji Lee, Beung-Chul Ahn, Min Hee Hong, Kyoung-Ho Pyo, Byoung Chul Cho
Förderung
- National Research Foundation of Korea
Zitieren
APA
Synn, C. B., Kim, S. E., Lee, H. K., Kim, M. H., Kim, J. H., Lee, J. M., Jo, H. N., Lee, W., Kim, D. K., Byeon, Y., Kim, Y. S., Yun, M. R., Park, C. W., Yun, J., Lim, S., Heo, S. G., Yang, S. D., Lee, E. J., Lee, S., …, & Cho, B. C. (2022). SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models. Clinical & Translational Immunology, 11(1). https://doi.org/10.1002/cti2.1364
Vancouver
Synn CB, Kim SE, Lee HK, Kim MH, Kim JH, Lee JM, et al. SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models. Clinical & Translational Immunology. 2022;11(1). doi:10.1002/cti2.1364
BibTeX
@article{Synn2022,
author = {Synn, Chun-Bong and Kim, Sung Eun and Lee, Hee Kyu and Kim, Min-Hwan and Kim, Jae Hwan and Lee, Ji Min and Jo, Ha Ni and Lee, Wongeun and Kim, Dong Kwon and Byeon, Youngseon and Kim, Young Seob and Yun, Mi Ran and Park, Chae-Won and Yun, Jiyeon and Lim, Sangbin and Heo, Seong Gu and Yang, San-Duk and Lee, Eun Ji and Lee, Seul and Choi, Hunmi and Lee, You Won and Cho, Jae Seok and Kim, Do Hee and Park, Sungho and Kim, Jung-Ho and Choi, Yewon and Lee, Sung Sook and Ahn, Beung-Chul and Kim, Chang Gon and Lim, Sun Min and Hong, Min Hee and Kim, Hye Ryun and Pyo, Kyoung-Ho and Cho, Byoung Chul},
title = {SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models},
journal = {Clinical & Translational Immunology},
year = {2022},
volume = {11},
number = {1},
doi = {10.1002/cti2.1364}
}
EUVIMED